Source: China – South China Morning PostClover Biopharmaceuticals, a Chinese biotech start-up that has developed a protein-based Covid-19 vaccine and is a supplier of Covax, said on Wednesday that trials showed the vaccine was 79 per cent effective against any severity of Covid-19 caused by the Delta variant.The study also showed the vaccine candidate, known as SCB-2019, was 92 per cent effective against the Gamma variant and 59 per cent against the Mu variant. The overall efficacy against all the strains in the study – including the…Read More